Colorectal Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Research evidence excerpt

Colorectal Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Biotechnology

EQUITY RESEARCH Industry Report

May 26, 2026

Colorectal Cancer: Key Takeaways from Cantor's 2nd

Research Analysts:

Olivia Brayer Saunders Annual Oncology Symposium

212-428-5907

Olivia.Brayer@cantor.com As part of Cantor's Oncology Symposium, we hosted a colorectal cancer

Eric Schmidt

212-294-7724 panel featuring Dr. Nevena Damjanov (Penn Medicine) and Dr. Allyson

Eric.Schmidt@cantor.com Ocean (Weill Cornell), whose practices are dedicated to GI malignancies.

Carter Gould

212-915-1794 We covered many topics, from the current treatment paradigm to several

Carter.Gould@cantor.com pipeline drugs in development (ADCs, RAS inhibitors, and bispecifics).

Sam Rodriguez, MD

212-915-1122 The key takeaway from our panel is that the treatment bar in 3L+ metastatic

Sam.Rodriguez@cantor.com colorectal cancer remains low, but not low enough to ignore quality-of-life.

Treatment landscape and importance of QoL in mCRC

●Earlier-line (1L & 2L) mCRC treatment is guided by tumor sidedness and

biomarker selection (BRAF, MSS/MSI, HER2, and RAS status).

●Unfortunately, the late-line (3L+) mCRC treatment setting is unguided

and has few attractive options, with even Lonsurf + bev delivering an

mOS of <1 year.

What are clinically meaningful benchmarks in 3L+ mCRC?

●ORR >5%

●mPFS > 6 months

●mOS >10 months

Quality-of-life matters nearly as much as tumor control:

●Our KOLs were both highly sensitive to safety/tolerability and a

patient's quality-of-life when considering which treatments to use in

the 3L+ setting.

●Double-digit rates of Grade ≥3 adverse events were viewed as difficult

to accept, especially when toxicities lead to ED visits or hospitalization.